
Opinion|Videos|October 25, 2024
Emerging Trends and Rising Prevalence of mCSPC
Key Takeaways
- Improved diagnostic techniques and an aging population contribute to the increasing prevalence of mCSPC.
- Earlier detection and personalized therapeutic strategies are becoming more common in mCSPC management.
Panelists discuss how the prevalence of metastatic castration-sensitive prostate cancer (mCSPC) has been increasing, potentially influenced by changes in prostate-specific antigen screening recommendations and rising diagnoses of metastatic hormone-sensitive prostate cancer.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following:
What is the prevalence of mCSPC? What trends have emerged in recent years?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
TULSA preserves penile length vs robotic prostatectomy in CAPTAIN trial
2
The UroOnc Minute: Optimizing Patient Follow-Up in Urologic Oncology, With Jason Hafron, MD
3
Can Aydogdu, MD on using ctDNA to predict nodal metastases at cystectomy
4
KEYNOTE-B15 data on enfortumab vedotin plus pembrolizumab in MIBC published in NEJM
5








